New hope for mystery cancers: immunotherapy shows promise
NCT ID NCT03752333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the immunotherapy drug pembrolizumab in 35 adults with cancer of unknown primary (CUP), a cancer that starts in an unknown location. Participants received the drug intravenously, and researchers measured how many saw their tumors shrink or disappear. The goal was to control the disease, not cure it, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gastrointestinal Units, The Royal Marsden NHS Foundation Trust (Sutton and Chelsea)
Sutton, Surrey, United Kingdom
-
Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
-
Hammersmith Hospital - Imperial College Healthcare NHS Trust
Hammersmith, London, W12 0HS, United Kingdom